228
Non-Exudative Macular Degeneration (AMD) (COMPLETE).
. Accessed in
30 March 2010.
58. A Study of Strontium90 Beta Radiation With Lucentis to Treat
Age-Related Macular Degeneration (CABERNET)
.
clinicaltrials.gov/ct2/show/NCT00454389?term=CABERNET
&rank=1. Accessed in 28 March 2010.
59. Safety Study for Treatment of Wet Macular Degeneration Using
the TheraSight(TM) Ocular Brachytherapy System
.
clinicaltrial.gov/ct2/show/NCT00100087?term=TheraSight&r
ank=1 Accessed in 28 March 2010.
60. Landa G, Butovsky O, Shoshani J, Schwartz M, Pollack A.
Weekly vaccination with Copaxone (glatiramer acetate) as a po-
tential therapy for dry age-related macular degeneration. Curr
Eye Res. 2008 Nov;33(11):1011-3.
61. Copaxone in Age Related Macular Degeneration.
-
caltrials.gov/ct2/show/NCT00466076. Accessed in 27 March
2010.
62. Stokkermans TJW. Treatment of age-related macular degenera-
tion, Clin Eye Vis Care 2000;12(1):15-35.
63. Mechanism of action. Othera Pharmaceuticals Inc. Web site.
. Accessed October 3,
2007.
64. OT-551 antioxidant eye drops to treat geographic atrophy in
age-related macular degeneration. ClinicalTrials.gov Web site.
Accessed March 27, 2010.
65. The OMEGA Study: Use of eye drops to treat geographic at-
rophy associated with age-related macular degeneration (dry
AMD). ClinicalTrials.gov Web site.
.
gov/ct/show/NCT00485394?order=1 Accessed 27 March,
2010.
66. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin
A arrest accumulation of toxic retinal fluorophores: a potential
therapy for treatment of lipofuscin based retinal diseases. Invest
Ophthalmol Vis Sci. 2005;46:4393-4401.
67. Study of fenretinide in the treatment of geographic atrophy
associated with age-related macular degeneration. Clinical-
Trials.gov Web site.
/
NCT00429936?order=1. Accessed 28 March 2010.
68. Z Yang. Toll-like receptor 3 and geographic atrophy in age-relat-
ed macular degeneration N Engl J Med 2008.
69. Kendall, R.L., Wang, G., and Thomas, K.A. (1996). Identifi-
cation of a Natural Soluble Form of the Vascular Endothelial
Growth Factor Receptor, FLT-1, and Its Heterodimerization
with KDR. Biochem Biophys Res Commun 226, 324-328.
70. Gehlbach, P., Demetriades, A.M., Yamamoto, S., Deering, T.,
Xiao, W.H., Duh, E.J., Yang, H.S., Lai, H., Kovesdi, I., Car-
rion, M., Wei, L., and Campochiaro, P.A. (2003b). Periocular
gene transfer of sFlt-1 suppresses ocular neovascularization and
vascular endothelial growth factor-induced breakdown of the
blood-retinal barrier. Hum Gene Ther 14, 129-141.
71. Honda, M., Sakamoto, T., Ishibashi, T., Inomata, H., andUeno,
H. (2000). Experimental subretinal neovascularization is inhib-
ited by adenovirus-mediated soluble VEGF/flt-1 receptor gene
transfection: a role of VEGF and possible treatment for SRN in
age-related macular degeneration. Gene Ther 7, 978-985.
72. Lai, C.M., Brankov, M., Zaknich, T., Lai, Y.K., Shen, W.Y.,
Constable, I.J., Kovesdi, I., and Rakoczy, P.E. (2001). Inhibi-
tion of angiogenesis by adenovirusmediateds Flt-1 expression in
a rat model of corneal neovascularization. Hum Gene Ther 12,
1299-1310.
73. Rota, R., Riccioni, T., Zaccarini, M., Lamartina, S., Gallo,
A.D., Fusco, A., Kovesdi, I., Balestrazzi, E., Abeni, D.C., Ali,
R.R., and Capogrossi, M.C. (2004). Marked inhibition of reti-
nal neovascularization in ratsfollowing soluble-flt-1 gene trans-
fer. J Gene Med 6, 992-1002.
74. Aiello, L.P., Pierce, E., Foley, E., Takagi, H., Chen, H.,Riddle,
L., Ferrara, N., King, G., and Smith, L. (1995a). Suppression
of retinal neovascularization in vivo by inhibition of vascular
endothelial growth factor (VEGF) using soluble VEGF-receptor
chimeric proteins. Proc Natl Acad Sci U S A 92, 10457-10461.
75. Bainbridge, J.W., Mistry, A., De Alwis, M., Paleolog, E., Baker,
A., Thrasher, A.J., and Ali, R.R. (2002). Inhibition of retinal
neovascularisation by gene transfer of soluble VEGF receptor
sFlt-1. Gene Ther 9, 320 326.
76. Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based
delivery of CNTF reduces photoreceptor degeneration in ani-
mal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci.
2002;43:3292-3298.
77. A Study of an Encapsulated Cell Technology (ECT) Implant for
Patients With Atrophic Macular Degeneration.
-
trials.gov/ct2/show/NCT00447954?term=neurotech&rank=3.
Accessed March , 2010.
78. ECT Technology. Neurotech Web site.
-
sa.com/product_tech.asp. Accessed on March, 2010.
79. Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final
multicenter investigation of rheopheresis for age related macular
degeneration (AMD) trial (MIRA-1) results. Trans Am Oph-
thalmol Soc. 2006;104:221-231=1.
80. Pulido JS, Multicenter Investigation of Rheopheresis for AMD
(MIRA-1) Study Group. Multicenter prospective, randomized,
doublemasked, placebo-controlled study of Rheopheresis to
treat nonexudative age-related macular degeneration: interim
analysis. Trans Am Ophthalmol Soc 2002;100:85-106; discus-
sion 106-7.
81. Rheopheresis Blood Filtration Study for the Treatment of Dry
Age-Related Macular Degeneration (AMD). Clinicaltrials.gov,
identifier NCT00078221.
82. Safety and Effectiveness Investigation for Dry, Non-Exudative
Age Related Macular Degeneration (AMD) Using Rheopheresis
(RHEO-AMD) Clinicaltrials.gov, identifier NCT00460967.
83.
.
84.
.
85. Fialho, Sílvia Ligório and Cunha Júnior, Armando da
Silva. Iontoforese no transporte ocular de drogas. Arq. Bras.
Oftalmol. [online]. 2004, vol.67, n.5, pp. 839-845. ISSN
0004-2749.
